Download PDF
Exp Clin Endocrinol Diabetes 2017; 125(03): 176-182
DOI: 10.1055/s-0042-116071
Article
© Georg Thieme Verlag KG Stuttgart · New York

Lipid Accumulation Product (LAP) as an Index of Metabolic and Hormonal Disorders in Aging Men

I. Rotter
1   Department of Medical Rehabilitation, Pomeranian Medical University in Szczecin, Szczecin, Poland
,
A. Rył
2   Department of Histology and Developmental Biology, Pomeranian Medical University in Szczecin, Szczecin, Poland
,
A. Szylińska
1   Department of Medical Rehabilitation, Pomeranian Medical University in Szczecin, Szczecin, Poland
,
W. Pawlukowska
1   Department of Medical Rehabilitation, Pomeranian Medical University in Szczecin, Szczecin, Poland
,
A. Lubkowska
3   Department of Physical Medicine and Functional Diagnostics, Pomeranian Medical University in Szczecin, Pomeranian Medical University in Szczecin, Szczecin, Poland
,
M. Laszczyńska
2   Department of Histology and Developmental Biology, Pomeranian Medical University in Szczecin, Szczecin, Poland
› Author Affiliations
Further Information

Publication History

received 16 May 2016
revised 09 August 2016

accepted 24 August 2016

Publication Date:
29 November 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Lipid accumulation product (LAP) is an index used for evaluating lipid overaccumulation in adults. Our study aimed at assessing associations between LAP and metabolic syndrome (MetS) and its components, age-related testosterone deficiency syndrome (TDS), low-density cholesterol (LDL), as well as HOMA-IR (insulin resistance ratio), insulin level in non-diabetics and total testosterone (TT), estradiol E2, dehydroepiandrosterone sulphate (DHEAs) and sex hormone-binding globulin (SHBG) in aging men.

313 men aged 50–75 were surveyed with regard to the prevalence of diabetes (T2DM) and hypertension (HT). Anthropometric measurements, including waist circumference and arterial pressure, were performed. We also determined the levels of fasting plasma glucose (FPG), total cholesterol (TC), high-density cholesterol (HDL), low-density cholesterol (LDL), triglyceride (TG), insulin, TT, SHBG, DHEAs, and E2.

Patients with diagnosed MetS, T2DM, HT, obesity, overweight and TDS had a significantly higher LAP compared to those without these conditions. LAP was significantly positively correlated with serum TC, FPG, insulin, DHEAs, as well as APB-systolic concentration, and negatively correlated with HDL, TT, and SHBG.

LAP may then be used as a simple and inexpensive biomarker of metabolic disorders, and in risk assessment related to testosterone deficiency in aging men.

Key words

lipid accumulation product - aging men - hormones - metabolic syndrome
 

  • References

  • 1 Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Dis 2005; 8: 5-26
    PubMedGoogle Scholar
  • 2 Roriz AK, Passos LC, de Oliveira CC et al. Evaluation of the accuracy of anthropometric clinical indicators of visceral fat in adults and elderly. PLoS One 2014; 9: 103499
    CrossrefPubMedGoogle Scholar
  • 3 Abraham TM, Pedley A, Massaro JM et al. Association betwen visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. Circulation 2015; 27: 1639-1647
    PubMedGoogle Scholar
  • 4 Corona G, Vignozzi L, Sforza A et al. Obesity and late-onset hypogonadism. Mol Cell Endocrinol 2015; 15: 120-133
    PubMedGoogle Scholar
  • 5 Chiang JK, Koo M. Lipid accumulation product: a simple and accurate index for predicting metabolic syndrome in Taiwanese people aged 50 and over. BMC Cardiovasc Dis 2012; 12: 78
    CrossrefPubMedGoogle Scholar
  • 6 Xiang S, Hua F, Chen L et al. Lipid accumulation product is related to metabolic syndrome in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2013; 121: 115-118
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Wakabayashi I, Daimon T. A strong association between lipid accumulation product and diabetes mellitus in japanese women and men. J Atheroscl Thromb 2014; 21: 282-288
    PubMedGoogle Scholar
  • 8 Nguyen-Duy TB, Nichaman MZ, Church TS et al. Visceral fat and liver fat are independent predictors of metabolic risk factors in men. Am J Physiology. Endocrinol Metab 2003; 284: 1065-1071
    PubMedGoogle Scholar
  • 9 Kahn HS. The Lipid Accumulation Product is better than BMI for identifying diabetes: a population-based comparison. Diabetes Care 2006; 29: 151-153
    CrossrefPubMedGoogle Scholar
  • 10 Ioachimescu AG, Brennan DM, Hoar BM et al. The Lipid Accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study. Obesity (Silver Spring) 2010; 18: 1836-1844
    CrossrefPubMedGoogle Scholar
  • 11 Gao X, Wang G, Wang A et al. Comparison of lipid accumulation product with body mass index as an indicator of hypertension risk among Mongolians in China. Obes Res Clin Practice 2013; 7: 308-314
    PubMedGoogle Scholar
  • 12 Blaya R, Thomaz LD, Guilhermano F et al. Total testosterone levels are correlated to metabolic syndrome components. Aging Male 2016; 9: 1-5
    PubMedGoogle Scholar
  • 13 Corona G, Monami M, Rastrelli G et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011; 8: 272-283
    CrossrefPubMedGoogle Scholar
  • 14 Brand JS, van der Tweel I, Grobbee DE et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 2011; 40: 189-207
    Google Scholar
  • 15 Bobjer J, Bogefors K, Isaksson S. High Prevalence of Hypogonadism and Associated Impaired Metabolic and Bone Mineral Status in Subfertile Men. Clin Endocrinol (Oxford) 2016 [Epub ahead of print]
    PubMed
  • 16 Kelly DM, Jones TH. Testosterone and obesity. Obes Rev 2015; 16: 581-606
    CrossrefPubMedGoogle Scholar
  • 17 Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol 2013; 217: R25-R45
    CrossrefPubMedGoogle Scholar
  • 18 Cohen P. The hypogonadal – obesity cycle. Med Hypotheses 1999; 52: 49-51
    CrossrefPubMedGoogle Scholar
  • 19 Morelli A, Sarchielli E, Comeglio P et al. Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol Cell Endocrinol 2014; 382: 107-119
    CrossrefPubMedGoogle Scholar
  • 20 Antonio L, Wu FC, O’Neill TW et al. Associations between sex steroids and the development of metabolic syndrome: a longitudinal study in European men. J Clin Endocrinol Metab 2015; 100: 1396-1404
    CrossrefPubMedGoogle Scholar
  • 21 Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-1062
    CrossrefPubMedGoogle Scholar
  • 22 Kula K, Słowikowska-Hilczer J. Late-onset hypoonadism in men. Endokrynol Pol 2012; 63: 15-19
    PubMedGoogle Scholar
  • 23 Morley JE, Charlton E, Patrick P et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239-1242
    CrossrefPubMedGoogle Scholar
  • 24 Taverna MJ, Martinez-Larrad MT, Frechtel GD et al. Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. Eur J Endocrinol 2011; 164: 559-567
    CrossrefPubMedGoogle Scholar
  • 25 Ejike CECC. Lipid accumulation product and waist-to-height ratio are predictors of the metabolic syndrome in a Nigerian male geriatric population. J Rural Trop Public Health 2011; 10: 101-105
    PubMedGoogle Scholar
  • 26 Motamed N, Razmjou S, Hemmasi G et al. Lipid accumulation product and metabolic syndrome: a population-based study in northern Iran. J Endocrinol Invest 2016; 39: 375-382
    CrossrefPubMedGoogle Scholar
  • 27 Zhong C, Xia W, Zhong X et al. Lipid Accumulation Product and Hypertension Related to Stroke: a 9.2-Year Prospective Study Among Mongolians in China. J Atheroscler Thromb 2016 [Epub ahead of print]
    PubMed
  • 28 Wakabayashi I. Associations of blood lipid-related indices with blood pressure and pulse pressure in middle-aged men. Metab Syndr Relat Disord 2015; 13: 22-28
    CrossrefPubMedGoogle Scholar
  • 29 Xia C, Li R, Zhang S et al. Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals. Eur J Clin Nutr 2012; 66: 1035-1038
    CrossrefPubMedGoogle Scholar
  • 30 Oh JY, Sung YA, Lee HJ. The lipid accumulation product as a useful index for identifying abnormal glucose regulation in young Korean women. Diabet Med 2013; 30: 436-442
    CrossrefPubMedGoogle Scholar
  • 31 Eckel RH, Kahn SE, Ferrannini E et al. Obesity and type 2 diabetes: what can be unified and what needs to be individualized?. J Clin Endocrinol Metab 2011; 96: 1654-1663
    CrossrefPubMedGoogle Scholar
  • 32 Urbanová M, Haluzik M. The role of adipose tissue in pathogenesis of type 2 diabetes mellitus. Cesk Fysiologie 2015; 64: 73-78
    PubMedGoogle Scholar
  • 33 Wanderley Rocha DR, Jorge AR, Braulio VB et al. Visceral adiposity measurements, metabolic and inflammatory profile in obese patients with and without type 2 diabetes mellitus: a cross-sectional analysis. Curr Diabetes Rev 2015 [Epub ahead of print]
    PubMed
  • 34 Vieira BA, Sauer P, Marcadenti A et al. Association between LAP Index (Lipid Accumulation Product) and metabolic profile in hospitalized patients. Nutr Hosp 2015; 31: 2771-2774
    PubMedGoogle Scholar
  • 35 Mirmiran P, Bahadoran Z, Azizi F. Lipid accumulation product is associated with insulin resistance, lipid peroxidation, and systemic inflammation in type 2 diabetic patients. Endocrinol Metab (Seoul) 2014; 29: 443-449
    CrossrefPubMedGoogle Scholar
  • 36 Lemieux I, Pascot A, Couillard C et al. Hypertriglyceridemic waist:A marker ofthe atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation 2000; 102: 179-184
    CrossrefPubMedGoogle Scholar
  • 37 Sam S, Haffner S, Davidson MH et al. Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. Diabetes Care 2009; 32: 1916-1920
    CrossrefPubMedGoogle Scholar
  • 38 Ebrahimi F, Christ-Crain M. Metabolic syndrome and hypogonadism- two peas in a pod. Swiss Medical Wkly 2016; 21: w14283
    PubMedGoogle Scholar
  • 39 Maturana MA, Moreira RM, Spritzer PM. Lipid accumulation product (LAP) is related to androgenicity and cardiovascular risk factors in postmenopausal women. Maturitas 2011; 70: 395-399
    CrossrefPubMedGoogle Scholar
  • 40 Camacho EM, Huhtaniemi IT, O’Neill TW et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013; 168: 445-455
    CrossrefPubMedGoogle Scholar
  • 41 Kapoor D, Aldred H, Clark S et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007; 30: 911-917
    CrossrefPubMedGoogle Scholar
  • 42 Bekaert M, Van Nieuwenhove Y, Calders P et al. Determinants of testosterone levels in human male obesity. Endocrine 2015; 50: 202-211
    CrossrefPubMedGoogle Scholar
  • 43 Wake DJ, Strand M, Rask E et al. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf) 2007; 66: 440-446
    CrossrefPubMedGoogle Scholar
  • 44 Dhindsa S, Furlanetto R, Vora M et al. Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes. Diabetes Care 2011; 34: 1854-1859
    CrossrefPubMedGoogle Scholar
  • 45 Tajar A, Forti G, O’Neill TW et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab 2010; 95: 1810-1818
    CrossrefPubMedGoogle Scholar
  • 46 Svartberg J, von Mühlen D, Sundsfjord J et al. Waist circumference and testosterone levels in community dwelling men. The Tromsø study. Eur J Epidemiol 2004; 19: 657-663
    CrossrefPubMedGoogle Scholar
  • 47 Rył A, Rotter I, Miazgowski T et al. Metabolic syndrome and benign prostatic hyperplasia: association or coincidence?. Diabetol Metab Syndr 2015; 7: 94
    CrossrefPubMedGoogle Scholar